携带BRCA1/2突变的携带者与一般乳腺癌患者 (N = 799,986):基于21基因测试的分子表征
Rinat Yerushalmi1,2, Adi Pomerantz3, Ron Lewin4
1Davidoff Cancer Center, Rabin Medical Center, 39 Jabotinski St, 49414, Petah Tikva, Israel. rinaty@clalit.org.il.
Breast cancer research and treatment
|April 3, 2024
概括
乳腺癌 (BC) 患者在BRCA1/2具有致病变体 (PV) 具有较高的21基因复发得分 (RS),由于不同的基因表达特征. 这些发现突出了瘤生物学上的差异,受BRCA1/2突变的影响.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 生物标志物 生物标志物
背景情况:
- 21基因复发分数 (RS) 测定对于指导早期,激素受体阳性,HER2-阴性乳腺癌 (BC) 的治疗决策至关重要.
- 在BRCA1/2基因中的生殖系致病变体 (PV) 与特定的BC亚型相关,可能影响瘤生物学和对治疗的反应.
研究的目的:
- 为了比较21基因复发得分 (RS) 在具有BRCA1/2致病变体 (PV) 的BC患者和一般BC患者之间的分布.
- 分析这些患者群体之间的基因表达特征的差异,包括单基因和基因组分数在21基因测定中的差异.
主要方法:
- 追溯分析81名女性ER+/HER2-BC患者的生殖系BRCA1/2 PV,他们接受了21基因测试.
- 将RS分布和基因表达数据与大型商用数据库 (CDB,N=799,986) 的比较.
- 统计分析使用千平方和一个样本的t测试来评估研究组和CDB之间的差异.
主要成果:
- 与一般BC人群相比,BRCA1/2 PV患者年轻,RS结果明显高 (49.4%与RS≥26的16.4%相比).
- 在测试中,16个癌症基因中的12个基因的表达,以及ER,增殖和入侵基因组得分,差异很大,导致BRCA1/2 PV组的RS更高.
- 这些观察到的差异在很大程度上保持在分层患者按更年期状态.
结论:
- 患有BRCA1/2致病变体的乳腺癌患者表现出更高的21基因复发得分.
- 这些高得分是由21基因测定中的大多数基因的独特基因表达特征驱动的,反映了瘤生物学中的潜在差异.
更多相关视频
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
12.3K
09:22Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
Published on: February 28, 2021
5.5K
相关概念视频
Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mismatch Repair
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
